News & Updates
Filter by Specialty:

Which factors predict mortality in advanced HCC?
01 Mar 2024
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
Which factors predict mortality in advanced HCC?
01 Mar 2024
Dietary niacin may protect against death in NAFLD
13 Feb 2024
byJairia Dela Cruz
Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.
Dietary niacin may protect against death in NAFLD
13 Feb 2024
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024
byAudrey Abella
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.